Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Twilio Inc (TWLO) vs 10X Genomics Inc (TXG) Price & Performance

Twilio IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Twilio Inc vs 10X Genomics Inc — how do they compare? Twilio Inc trades at $227.45 (market cap $34.69B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Twilio Inc is far larger — about 4.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Twilio Inc nearer its low. Which is the better fit depends on your goals.

TWLOTXG
Market Cap
$34.69B$8.55B
Sector
TechnologyHealth
52-Week High
$255.95$67.29
52-Week Low
$100.09$11.34
Enterprise Value
$33.10B$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Twilio Inc

Twilio (TWLO) trades at $225.89, down 3.04% today, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with a 20.62% net income margin in 2025, reversing previous losses, while technical indicators show a neutral stance with support at $222 and resistance at $230.

The outlook remains positive with 77% analyst buy ratings and a $266.31 consensus price target, representing 18% upside potential. Key risks include execution of AI strategy and competitive pressures in communications infrastructure, but strong free cash flow generation and strategic positioning for AI-driven customer engagement support the bullish case.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Twilio Inc

Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

Read more on TWLO

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG